Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: results of a randomized phase I/II clinical trial

Saved in:
Bibliographic Details
Published in:Frontiers in hematology 2023-09, Vol.2
Main Authors: Abdallah, Al-Ola, Lesokhin, Alexander, Wrobel, Tomasz, Jamroziak, Krzysztof, Dytfeld, Dominik, Touzeau, Cyrille, Suvannasankha, Attaya, Leleu, Xavier, Silbermann, Rebecca, Khan, Abdullah M., Kumar, Shaji, Gertz, Morie, Laubach, Jacob P., Jou, Ying-Ming, Bar, Merav, Das, Prianka, Wang, Yu, Demers, Korey, Stong, Nicholas, Perumal, Deepak, La Motte-Mohs, Ross, MacLachlan, Kylee, Dimopoulos, Meletios-Athanasios
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2813-3935
2813-3935
DOI:10.3389/frhem.2023.1244494